Download PARTNER SEARCH FORM

INFORMAL GROUP OF R&D LIAISON OFFICES (IGLO)
PARTNER SEARCH FORM
AREA OF INTEREST:
DATE OF PUBLICATION OF THIS FORM: 24/07/07
ANSWERS EXPECTED BEFORE: 20/08/07
GENERAL INFORMATION
NAME OF ORGANISATION*: PHERECYDES PHARMA
TYPE OF ORGANISATION*:
Public body (Research organization/university/lab)  SME/ SME association
Not for profit organization
Regional body/agency
Other (specify)
Other private actor
CONTACT PERSON
NAME*
Marie-Laure GARRIGUES
FRANCE
COUNTRY
ADDRESS
48 rue de Lisbonne
75008 PARIS FRANCE
TEL*
FAX
E-MAIL*
+33 (0) 6 87 09 50 16
[email protected]
TYPE OF PARTNER SEARCH*:
FP7 SPECIFIC CALL
NO SPECIFIC CALL/EXPRESSION OF INTEREST (ONLY IF RELEVANT)
CONSORTIUM*
POSITION WITHIN CONSORTIUM*
Create a new consortium
Join an existing consortium
As a Coordinator
As a Partner
IF FP7 RELEVANT CALL:
AREA OF INTEREST
* Compulsory
1
INFORMAL GROUP OF R&D LIAISON OFFICES (IGLO)
PARTNER SEARCH FORM
COOPERATION
CAPACITIES
1 – Health
2 - Food, agriculture, fisheries and biotechnologies
3 – ICT
4 – NMP
5 – Energy
6 – Environment (including climate change)
7 – Transports (including aeronautics)
8 – SSH
9 – Space
10 – Security
Research infrastructures
Research for the profit of SMEs
Regions of knowledge
Research potential
Science in society
Support to the coherent development of research policies
International cooperation
PEOPLE
IDEAS
Initial Training networks Networks (ITN)
Intra European fellowship (IEF)
European Reintegration Grants (ERG)
Cofunding (COFUND)
Industry-Academia Partnerships and Pathways (IAPP)
International Outgoing Fellowships (IOF)
International Incoming Fellowships (IIF)
International Reintegration grant (ERG)
Marie Curie “Researchers’night”
Marie Curie Awards
Starting Independent research grant
Advanced Investigator grants
EURATOM
JRC
CALL DETAILS
CALL IDENTIFICATION (according DATE OF PUBLICATION:
to WP): HEALTH-2007-2.3.1-1
June 19th 2007
CLOSURE DATE:
September 18th 2007
PROJECT INFORMATION
ACRONYME & TITLE: Novel targets for drugs against Gram negative bacteria
* Compulsory
2
INFORMAL GROUP OF R&D LIAISON OFFICES (IGLO)
PARTNER SEARCH FORM
SUMMARY*:
PHERECYDES PHARMA
THE TECHNOLOGY
Pherecydes Pharma’s technology targets bacteriophages, the natural viruses of bacteria. Despite very efficient properties
for specific detection and rapid lysis of bacteria, phages have not yet been fully exploited as biotechnological tools due to
the inefficient process of selecting them from nature. Our phage libraries are produced by stochastic recombination within
three key proteins of the targeting system of phages. The range of specificities is thus extended so as to potentially
address any infectious problems due to new or emergent bacterial species. These flexible tools are incorporated into
miniaturized detection devices and enter into the composition of solutions for neutralization of bacteria.
TECHNICAL DESCRIPTION
The phage genes encoding proteins 12, 36 and 37, which bind to receptors on the bacterial surface are mutated at specific
zones, and cloned in recombination vectors. A population of transformed bacteria is obtained, containing a variety of
inserts. Infection by a T4 phage leads to a phage progeny representing a huge diversity of specificities. The library is then
further characterized by testing with collection strains.
INDUSTRIAL APPLICATION
Progress in the biotechnological exploitation of phages is ongoing: understanding of phage molecular biology has been
exploited to generate novel nanotechnologies like biosensors for diagnostics, and new bacteriophage-based therapies are
emerging for the management of hospital infections or problems involving bacterial biofilms. Pherecydes Pharma focuses
on emergent infectious problems that are resistant to current strategies.
ADDED VALUE
The high specificity of phages for their bacterial host is a key attribute, resulting in a high efficiency compared to classical
antibiotic strategies or compared to molecular tools (DNA, antibodies) for diagnostics. The construction of a bacteriophage
library by means of a stochastic recombination of proteins expressed at the tip of tail fibers confers host range expansion
and allows extended applications of these technologies.
CONTRIBUTION
Pherecydes Pharma would develop therapeutic applications of its bacteriophage librairies, the diversification of phage
proteins targeting bacteria may permit a very efficient action against Gram negative bacteria.
KEYWORDS: Human Therapeutics; Phage; Bacteria; Drug Target; Gram Negative Bacteria.
TYPE OF PROJECT Funding scheme: Collaborative projects (Small or medium-scale focused research projects with
maximum EC contribution of € 6,000,000/project).
PARTNERS ALREADY INVOLVED ( Contact Name, Name of organization, e-mail address):
PARTNER SOUGHT
COUNTRY (IES) (if relevant):
* Compulsory
3
INFORMAL GROUP OF R&D LIAISON OFFICES (IGLO)
PARTNER SEARCH FORM
EXPERTISE REQUESTED*:
Pherecydes Pharma holds two patents covering the process of production of the bacteriophage libraries. We have started library
production in collaboration with institutional partners. We now seek partners to transform the unlimited specificity of our phage
library into the new tools for bacterial infections control. Specifically, we seek strategic partners for biosensor and pharmaceutical
developments.
ROLE:  Technology development
 Dissemination
ORGANISATION TYPE:
 Research
 Demonstration
 Training
 Other (specify): …………….
Public body (Research organization/university/lab)  SME/ SME association
Not for profit organization
Regional body/agency
Other private actor
Other (specify)
 Any
HOW MANY PARTNERS ARE REQUIRED?
* Compulsory
4